Press release
Colorectal Cancer Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Colorectal Cancer Clinical Trials
Explore our comprehensive Colorectal Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Colorectal Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Colorectal Cancer Pipeline Report
• In September 2024:- Bristol-Myers Squibb- A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
• In August 2024:- Seagen Inc.- This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• DelveInsight's Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Colorectal Cancer treatment.
• The leading Colorectal Cancer Companies working in the market include Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Promising Colorectal Cancer Therapies in the various stages of development include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
Find out more about Colorectal Cancer treatment drugs @ Drugs for Colorectal Cancer Treatment- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Colorectal Cancer Emerging Drugs Profile
• XL092 : Exelixis
XL092 is an investigational small molecule, oral tyrosine kinase inhibitors (TKI) that inhibits the activity of receptor tyrosine kinases involved in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes like oncogenesis, metastasis, and tumor angiogenesis. Currently it is in Phase III stage of clinical trial evaluation to treat Colorectal Cancer.
• Adagrasb : Mirati Therapeutics
Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers. The drug candidate is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated colorectal cancer. Currently being evaluated in the Phase III studies.
• Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
Olaparib is an investigational is a first-in-class Poly (ADP-ribose) polymerase PARP inhibitors and the first targeted treatment that potentially exploit DNA damage response (DDR) pathway deficiencies, like BRCA mutations, to preferentially kill cancer cells. Olaparib is being jointly developed and commercialized by AstraZeneca and Merck. Currently the drug is being evaluated in Phase III for the treatment of Colorectal Cancer.
• DS-8201: Daiichi Sankyo
DS-8201 a proprietary antibody-drug conjugate (ADC) is a smart chemotherapy comprised of a humanized HER2 antibody attached to a novel topoisomerase I inhibitor payload by a tetra peptide-based linker. It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered. The drug is been developed in collaboration with AstraZeneca. The drug is in Phase II stage of clinical trials.
• Ompenaclid: Inspirna
Ompenaclid is a first in class oral small molecule inhibitor of the creatine transport channel SLC6A8 a novel target that is enriched under hypoxic conditions and provides tumor cells with an additional energy source. Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells. It is based on Rgenix technology. The drug is in Phase II stage of clinical trials.
• LYL845: Lyell Immunopharma
LYL845, an autologous tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform is currently being investigated in a Phase 1 clinical trial in patients suffering with relapsed or refractory metastatic colorectal cancer.
• RG6286: Genentech
RG6286 (BLYG-8824A) is under development for the treatment of relapsed or refractory, advanced, or metastatic colorectal cancer. It is new chemical entity, administered through an intravenous route currently being investigated in a Phase 1 clinical trial.
Dive into our Colorectal Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Colorectal Cancer Treatment Therapies- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Colorectal Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Dive into our detailed Colorectal Cancer Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Colorectal Cancer Products, Companies, and Unmet Needs- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Colorectal Cancer Pipeline Report
• Coverage- Global
• Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
Gain valuable insights into emerging therapies and innovations with our Colorectal Cancer Pipeline Report @ Colorectal Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Colorectal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. XL092: Exelixis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Early Stage Products (Phase I)
12. LYL845: Lyell Immunopharma
13. Inactive Products
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Colorectal Cancer - Unmet Needs
17. Colorectal Cancer - Market Drivers and Barriers
18. Colorectal Cancer - Future Perspectives and Conclusion
19. Colorectal Cancer Analyst Views
20. Colorectal Cancer Key Companies
21. Appendix
Trending Reports:
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acrocallosal Syndrome Market: https://www.delveinsight.com/report-store/acrocallosal-syndrome-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Adrenogenital Syndrome Market: https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Corneal Ulcer Market: https://www.delveinsight.com/report-store/corneal-ulcer-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Stable Angina Market: https://www.delveinsight.com/report-store/stable-angina-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/left-ventricular-dysfunction-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-refractory-gout-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colorectal Cancer Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight here
News-ID: 3709312 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
